11294 Federal Register / Vol. 86, No. 35 / Wednesday, February 24, 2021 / Notices 

information whose disclosure is 

restricted by statute. 

Submit written comments and 

recommendations to OMB for the 

proposed information collection within 

30 days of publication of this notice to 

www.reginfo.gov/public/do/PRAMain. 

Find this particular information 

collection by selecting ‘‘Currently under 

30-day Review—Open for Public 

Comments’’ or by using the search 

function. 

FOR FURTHER INFORMATION CONTACT: 

Patrick Yellin, Monitoring, Assistance, 

and Media Programs Division, Office of 

Compliance, Mail Code 2227A, 

Environmental Protection Agency, 1200 

Pennsylvania Ave. NW, Washington, DC 

20460; telephone number: (202) 564– 

2970; fax number: (202) 564–0050; 

email address: yellin.patrick@epa.gov. 

SUPPLEMENTARY INFORMATION: 

Supporting documents, which explain 

in detail the information that EPA will 

be collecting, are available in the public 

docket for this ICR. The docket can be 

viewed online at www.regulations.gov, 

or in person at the EPA Docket Center, 

WJC West, Room 3334, 1301 

Constitution Ave. NW, Washington, DC. 

The telephone number for the Docket 

Center is 202–566–1744. For additional 

information about EPA’s public docket, 

visit: http://www.epa.gov/dockets. 

Abstract: Owners and operators of 

affected facilities are required to comply 

with reporting and recordkeeping 

requirements for the General Provisions 

(40 CFR part 63, subpart A), as well as 

the applicable standards at 40 CFR part 

63, subpart W. This includes submitting 

initial notifications, performance tests 

and periodic reports and results, and 

maintaining records of the occurrence 

and duration of any startup, shutdown, 

or malfunction in the operation of an 

affected facility, or any period during 

which the monitoring system is 

inoperative. These reports are used by 

EPA to determine compliance with 

these standards. 

Form Numbers: None. 

Respondents/affected entities: Epoxy 

resin and non-nylon polyamide resin 

production facilities. 

Respondent’s obligation to respond: 

Mandatory (40 CFR part 63, subpart W). 

Estimated number of respondents: 7 

(total). 

Frequency of response: Initially, 

quarterly, and semiannually. 

Total estimated burden: 3,940 hours 

(per year). Burden is defined at 5 CFR 

1320.3(b). 

Total estimated cost: $476,000 (per 

year), which includes $14,000 in 

annualized capital/startup and/or 

operation & maintenance costs. 

Changes in the Estimates: There is no 

increase in burden from the most 

recently approved ICR as currently 

identified in the OMB Inventory of 

Approved Burdens. This is due to two 

considerations: (1) The regulations have 

not changed over the past three years, 

and they are not anticipated to change 

over the next three years; (2) the growth 

rate for this industry is either very low 

or non-existent, so there is no 

significant change in the overall burden. 

However, there is a slight increase in 

costs. The operation and maintenance 

(O&M) costs have been updated from 

1998 dollars to 2019 dollars using the 

CEPCI CE Index. 

Courtney Kerwin, 

Director, Regulatory Support Division. 

[FR Doc. 2021–03793 Filed 2–23–21; 8:45 am] 

BILLING CODE 6560–50–P 

FEDERAL TRADE COMMISSION 

Granting of Requests for Early 

Termination of the Waiting Period 

Under the Premerger Notification 

Rules 

Section 7A of the Clayton Act, 15 

U.S.C. 18a, as added by Title II of the 

Hart-Scott-Rodino Antitrust 

Improvements Act of 1976, requires 

persons contemplating certain mergers 

or acquisitions to give the Federal Trade 

Commission and the Assistant Attorney 

General advance notice and to wait 

designated periods before 

consummation of such plans. Section 

7A(b)(2) of the Act permits the agencies, 

in individual cases, to terminate this 

waiting period prior to its expiration 

and requires that notice of this action be 

published in the Federal Register. 

The following transactions were 

granted early termination—on the dates 

indicated—of the waiting period 

provided by law and the premerger 

notification rules. The listing for each 

transaction includes the transaction 

number and the parties to the 

transaction. The Federal Trade 

Commission and the Assistant Attorney 

General for the Antitrust Division of the 

Department of Justice made the grants. 

Neither agency intends to take any 

action with respect to these proposed 

acquisitions during the applicable 

waiting period. 

EARLY TERMINATIONS GRANTED

[01/01/2021 12:00:00 a.m., 01/31/2021 12:00:00 a.m.] 

01/04/2021 

20210673 ........ G TransDigm Group Incorporated; AI Convoy (Cayman) Limited; TransDigm Group Incorporated. 

20210692 ........ G Marlin Equity V, L.P.; Luminate Capital Partners, LP; Marlin Equity V, L.P. 

20210695 ........ G Partners Group Access 77 PF LP; New Mountain Partners IV, L.P.; Partners Group Access 77 PF LP. 

20210697 ........ G Aurora Innovation, Inc; Uber Technologies, Inc; Aurora Innovation, Inc. 

20210698 ........ G Uber Technologies, Inc.; Aurora Innovation, Inc; Uber Technologies, Inc. 

20210699 ........ G Howard W. Lutnick; View, Inc.; Howard W. Lutnick. 

20210701 ........ G Humana Inc.; Rajendra K. Bansal; Humana Inc. 

20210702 ........ G Star Peak Energy Transition Corp.; Stem, Inc.; Star Peak Energy Transition Corp. 

20210703 ........ G Columna Datamars S.a.r.l; Datamars Investments S.a.r.l.; Columna Datamars S.a.r.l. 

20210708 ........ G Warburg Pincus Global Growth, L.P.; Tony Olson; Warburg Pincus Global Growth, L.P. 

20210709 ........ G L Catterton IX, L.P.; Truck Hero Holdings, Inc.; L Catterton IX, L.P. 

20210713 ........ G SK Holdings Co., Ltd.; Roivant Sciences Ltd.; SK Holdings Co., Ltd. 

20210718 ........ G AbbVie Inc.; Eiger BioPharmaceuticals, Inc.; AbbVie Inc. 

01/11/2021 

20210700 ........ G Huntsman Corporation; Audax Private Equity Fund IV AIV, L.P.; Huntsman Corporation. 

20210712 ........ G Andrea Pignataro; Flexpoint Fund III, L.P; Andrea Pignataro. 

20210719 ........ G OCM RGCY PT, L.P. ; Drake Kennedy; OCM RGCY PT, L.P. 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 86, No. 35 / Wednesday, February 24, 2021 / Notices 11295 

EARLY TERMINATIONS GRANTED—Continued 

[01/01/2021 12:00:00 a.m., 01/31/2021 12:00:00 a.m.] 

20210723 ........ G Leidos Holdings, Inc; Sumeet Singh; Leidos Holdings, Inc. 

20210724 ........ G Roger S. Penske; Roger S. Penske; Roger S. Penske. 

20210732 ........ G Rhone Partners V L.P.; Gruppo Illy S.p.A; Rhone Partners V L.P. 

20210733 ........ G Fiserv, Inc.; Ondot Systems, Inc.; Fiserv, Inc. 

20210734 ........ G Primoris Services Corporation; Future Infrastructure Holdings, LLC; Primoris Services Corporation. 

01/12/2021 

20210728 ........ G The Veritas Capital Fund VII, L.P.; Northrop Grumman Corporation; The Veritas Capital Fund VII, L.P. 

20210729 ........ G The Veritas Capital Fund VII, L.P.; The Veritas Capital Fund V, L.P.; The Veritas Capital Fund VII, L.P. 

20210740 ........ G Mercuria Energy Group Holding Ltd.; HC2 Holdings, Inc; Mercuria Energy Group Holding Ltd. 

20210741 ........ G CCP III AIV V, L.P. ; New Speedcast Parent; CCP III AIV V, L.P. 

20210742 ........ G Magna International Inc.; Dr. Geeta Gupta and Henrik Fisker; Magna International Inc. 

20210746 ........ G Oaktree Opportunities Fund XI, L.P.; S1 Blocker Buyer, Inc.; Oaktree Opportunities Fund XI, L.P. 

20210747 ........ G The Huron Fund V L.P.; Doug DeClusin; The Huron Fund V L.P. 

20210748 ........ G Partners Group Access 75 PF LP; New Harbor Wedgewood; Partners Group Access 75 PF LP. 

01/13/2021 

20210737 ........ G Oshkosh Corporation; James F. Miller; Oshkosh Corporation. 

20210749 ........ G PTC Inc.; JMI Equity Fund VIII–A, L.P.; PTC Inc. 

20210750 ........ G Total SE; Dong Kwan Kim; Total SE. 

20210752 ........ G Alexander Karp; Palantir Technologies Inc.; Alexander Karp. 

20210753 ........ G Stephen Cohen; Palantir Technologies Inc.; Stephen Cohen. 

20210756 ........ G H.I.G. Middle Market LBO Fund III, L.P.; Incline Equity Partners IV, L.P.; H.I.G. Middle Market LBO Fund III, L.P. 

20210757 ........ G Paysafe Limited; Paysafe Group Holdings Limited; Paysafe Limited. 

20210758 ........ G William P. Foley, II; Paysafe Group Holdings Limited; William P. Foley, II. 

20210759 ........ G Cannae Holdings, Inc.; Paysafe Group Holdings Limited; Cannae Holdings, Inc. 

20210762 ........ G Cronos TopCo LP; New Mountain Partners V, L.P.; Cronos TopCo LP. 

20210768 ........ G Murphy USA Inc.; Dean C. Durling; Murphy USA Inc. 

20210777 ........ G Fortress Credit Opportunities Fund V (G) L.P.; Fidentia Fortuna Holdings, Ltd.; Fortress Credit Opportunities Fund V (G) 

L.P. 

20210778 ........ G Vesper Healthcare Acquisition Corp.; LCP Edge Holdco, LLC; Vesper Healthcare Acquisition Corp. 

20210779 ........ G United States Steel Corporation; Big River Steel Holdings LLC; United States Steel Corporation. 

20210782 ........ G Jonathan Oringer; Shutterstock, Inc.; Jonathan Oringer. 

01/15/2021 

20210173 ........ S Albertsons Companies, Inc.; KB US Holdings, Inc.; Albertsons Companies, Inc. 

20210380 ........ G Allied Universal Topco LLC; Frank and Kathleen Argenbright; Allied Universal Topco LLC. 

20210760 ........ G ContourGlobal L.P.; Harbert Power Fund V, LLC; ContourGlobal L.P. 

20210775 ........ G Amphenol Corporation; MTS Systems Corporation ; Amphenol Corporation. 

20210783 ........ G KPS Special Situations Fund IV, LP; Ernest W. Giddens; KPS Special Situations Fund IV, LP. 

20210787 ........ G TCV X, L.P.; Newsela Inc.; TCV X, L.P. 

20210790 ........ G Kemper Corporation; American Access Group, LLC; Kemper Corporation. 

20210791 ........ G Silver Spike Acquisition Corp.; WM Holding Company, LLC; Silver Spike Acquisition Corp. 

20210794 ........ G Charlesbank Equity Fund IX, Limited Partnership; SPC Partners V, L.P.; Charlesbank Equity Fund IX, Limited Partnership. 

20210795 ........ G LPL Financial Holdings Inc.; Macquarie Group Limited; LPL Financial Holdings Inc. 

20210796 ........ G American Securities Partners VIII, L.P.; Beacon Roofing Supply, Inc.; American Securities Partners VIII, L.P.

20210797 ........ G Koninklijke Philips N.V.; Francisco Partners Agility, L. P.; Koninklijke Philips N.V. 

20210798 ........ G The Resolute Fund V, L.P.; Madison Dearborn Capital Partners VII–A, L.P.; The Resolute Fund V, L.P. 

20210799 ........ G Stillfront Group AB; Super Free Games, Inc.; Stillfront Group AB. 

20210800 ........ G United Therapeutics Corporation; Y-mAbs Therapeutics, Inc.; United Therapeutics Corporation. 

20210801 ........ G Temasek Holdings (Private) Limited; Kazuhide Nakano; Temasek Holdings (Private) Limited. 

20210803 ........ G Macquarie Group Limited; Waddell & Reed Financial, Inc.; Macquarie Group Limited. 

20210804 ........ G TC Energy Corporation; TC PipeLines, LP; TC Energy Corporation. 

20210805 ........ G The Veritas Capital Fund VII, L.P.; HMS Holdings Corp.; The Veritas Capital Fund VII, L.P. 

20210806 ........ G Matthew Rabinowitz; Natera, Inc.; Matthew Rabinowitz. 

20210808 ........ G Cerner Corporation; Bain Capital Europe Fund V, SCSp; Cerner Corporation. 

20210843 ........ G George Archos; Majesta Minerals, Inc.; George Archos. 


khammond on DSKJM1Z7X2PROD with NOTICES
11296 Federal Register / Vol. 86, No. 35 / Wednesday, February 24, 2021 / Notices 

FOR FURTHER INFORMATION CONTACT: 

Theresa Kingsberry (202–326–3100), 

Program Support Specialist, Federal 

Trade Commission Premerger 

Notification Office, Bureau of 

Competition, Room CC–5301, 

Washington, DC 20024. 

By direction of the Commission. 

Joel Christie, 

Acting Secretary. 

[FR Doc. 2021–03751 Filed 2–23–21; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

CE21–002: Research Grants to Develop 

or Identify Effective Strategies to 

Prevent Overdose Involving Illicit 

Stimulants and Polysubstance Use 

Involving Stimulants. 

Dates: June 15–16, 2021. 

Times: 8:30 a.m.–5:00 p.m., EDT. 

Place: Videoconference. 

Agenda: To review and evaluate grant 

applications. 

FOR FURTHER INFORMATION CONTACT: 

Mikel Walters, Ph.D., Scientific Review 

Officer, National Center for Injury 

Prevention and Control, CDC, 4770 

Buford Highway NE, Mailstop F–63, 

Atlanta, Georgia 30341, Telephone (404) 

639–0913, MWalters@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–03744 Filed 2–23–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Toxic Substances and 

Disease Registry 

[60Day–20–0051; Docket No. ATSDR–2020– 

0005] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Agency for Toxic Substances 

and Disease Registry (ATSDR), 

Department of Health and Human 

Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Agency for Toxic 

Substances and Disease Registry 

(ATSDR), as part of its continuing effort 

to reduce public burden and maximize 

the utility of government information, 

invites the general public and other 

Federal agencies the opportunity to 

comment on a proposed and/or 

continuing information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled ‘‘Assessment of 

Chemical Exposures (ACE) 

Investigations.’’ The purpose of ACE 

Investigations is to focus on performing 

rapid epidemiological assessments to 

assist state, regional, local, or tribal 

health departments (the requesting 

agencies) to respond to or prepare for 

acute environmental incidents. 

DATES: ATSDR must receive written 

comments on or before April 26, 2021. 

ADDRESSES: You may submit comments, 

identified by Docket No. ATSDR–2020– 

0005 by any of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS–D74, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. ATSDR will post, 

without change, all relevant comments 

to Regulations.gov. 

Please note: Submit all comments through 

the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS– 

D74, Atlanta, Georgia 30329; phone: 

404–639–7118; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses. 

5. Assess information collection costs. 

Proposed Project 

Assessment of Chemical Exposures 

(ACE) Investigations (OMB Control No. 

0923–0051)—Reinstatement with 


khammond on DSKJM1Z7X2PROD with NOTICES